Switch theme
Sign up to access all valuation multiples
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.
1997
88
Last FY Revenue $24.3M
Last FY EBITDA -$6.6M
$14.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Biofrontera achieved revenue of $24.3M and an EBITDA of -$6.6M.
Biofrontera expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biofrontera valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $24.3M | XXX | XXX | XXX |
| Gross Profit | XXX | $18.4M | XXX | XXX | XXX |
| Gross Margin | XXX | 75% | XXX | XXX | XXX |
| EBITDA | XXX | -$6.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -27% | XXX | XXX | XXX |
| EBIT | XXX | -$6.7M | XXX | XXX | XXX |
| EBIT Margin | XXX | -27% | XXX | XXX | XXX |
| Net Profit | XXX | -$4.9M | XXX | XXX | XXX |
| Net Margin | XXX | -20% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Biofrontera's stock price is EUR 2 (or $3).
Biofrontera has current market cap of EUR 15.1M (or $17.0M), and EV of EUR 12.6M (or $14.2M).
See Biofrontera trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14.2M | $17.0M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Biofrontera has market cap of $17.0M and EV of $14.2M.
Biofrontera's trades at 0.6x EV/Revenue multiple, and -2.1x EV/EBITDA.
Equity research analysts estimate Biofrontera's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biofrontera's P/E ratio is not available.
See valuation multiples for Biofrontera and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $17.0M | XXX | $17.0M | XXX | XXX | XXX |
| EV (current) | $14.2M | XXX | $14.2M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -2.1x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -2.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -3.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBiofrontera's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
Biofrontera's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biofrontera's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Biofrontera and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -27% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 103% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biofrontera acquired XXX companies to date.
Last acquisition by Biofrontera was XXXXXXXX, XXXXX XXXXX XXXXXX . Biofrontera acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Biofrontera founded? | Biofrontera was founded in 1997. |
| Where is Biofrontera headquartered? | Biofrontera is headquartered in Germany. |
| How many employees does Biofrontera have? | As of today, Biofrontera has 88 employees. |
| Is Biofrontera publicy listed? | Yes, Biofrontera is a public company listed on ETR. |
| What is the stock symbol of Biofrontera? | Biofrontera trades under B8FK ticker. |
| When did Biofrontera go public? | Biofrontera went public in 2007. |
| Who are competitors of Biofrontera? | Similar companies to Biofrontera include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Biofrontera? | Biofrontera's current market cap is $17.0M |
| Is Biofrontera profitable? | Yes, Biofrontera is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
